7 Results

People

  1. Kris
    Kris
  2. Chang
    Chang
  3. Drilon
    Drilon
  4. Falcon
    Falcon
  5. Rekhtman
    Rekhtman
  6. Yang
    Yang
  7. Berger
    Berger
  8. Chaft
    Chaft
  9. Chen
    Chen
  10. Donoghue
    Donoghue

Groups

  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Thoracic Oncology (7)
  4. GME, Medicine (2)
  5. Graduate Medical Education (2)
  6. Advanced Practice Providers (1)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  8. Body Imaging Service (1)
  9. Center for Pancreatic Cancer Research (1)
  10. Early Drug Development Service (1)
  1. "Mark Kris"
  2. "Annals of Oncology"
  3. "Oxford University Press"
  4. "Meeting abstract"
Formats
  1. Meeting Abstract (7)
Groups
  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Thoracic Oncology (7)
  4. GME, Medicine (2)
  5. Graduate Medical Education (2)
  6. Advanced Practice Providers (1)

More Groups

People
  1. Mark Kris (7)
  2. Alexander Drilon (2)
  3. Christina Falcon (2)
  4. Jason Chang (2)
  5. Natasha Rekhtman (2)
  6. Soo Ryum Yang (2)

More People

Years
  1. 2023 (2)
  2. 2021 (1)
  3. 2014 (1)
  4. 2012 (2)
  5. 2004 (1)
Publications
  1. Annals of Oncology (7)
Publishers
  1. Oxford University Press (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of cabozantinib in patients with MET-altered lung cancers
    Meeting Abstract

    Harada, G.; Santini, F. C.; Repetti, R. W.; Chang, J.; Yang, S. R.; Lin, Y. T.; Moses, K. A.; Falcon, C.; Wilhelm, C. J.; Goldstein, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
    Meeting Abstract

    Kris, M. G.; Grindheim, J. M.; Chaft, J. E.; Lee, J. M.; Johnson, B. E.; Rusch, V. W.; Bunn, P. A.; Pass, H.; Schum, E.; Carlisle, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program (MAP) at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Krug, L. M.; Pietanza, M. C.; Varghese, A. M.; Won, H.; Wang, L.; Rekhtman, N.; Travis, W. D.; Litvak, A.; Paik, P. K.; Riely, G. J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Mok, T.; Ou, S. H. I.; Martins, R. G.; Kim, D. W.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, S. P.; Jänne, P. A.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers
    Meeting Abstract

    Kris, M.; Goldberg, Z.; Jänne, P. A.; Kim, D.; Martins, R.; Mok, T. S. K.; O'Connell, J.; Ou, S.; Taylor, I.; Zhang, H.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Elucidating mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Pao, W.; Miller, V. A.; Kris, M. G.; Varmus, H. E.
    Annals of Oncology (2004)

    Fulltext@MSK | Save